ÒÎÐ 5 ñòàòåé: Ìåòîäè÷åñêèå ïîäõîäû ê àíàëèçó ôèíàíñîâîãî ñîñòîÿíèÿ ïðåäïðèÿòèÿ Ïðîáëåìà ïåðèîäèçàöèè ðóññêîé ëèòåðàòóðû ÕÕ âåêà. Êðàòêàÿ õàðàêòåðèñòèêà âòîðîé ïîëîâèíû ÕÕ âåêà Õàðàêòåðèñòèêà øëèôîâàëüíûõ êðóãîâ è åå ìàðêèðîâêà Ñëóæåáíûå ÷àñòè ðå÷è. Ïðåäëîã. Ñîþç. ×àñòèöû ÊÀÒÅÃÎÐÈÈ:
|
Õ³ðóðã³÷íå âòðó÷àííÿ ó ïàö³ºíò³â, ÿê³ ïðîõîäÿòü àíòèòðîìáîöèòàðíó òåðàï³þ 10 ñòðàíèöà782. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ,Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A, Intracoronary S, AntithromboticRegimen-Rapid Early Action for Coronary Treatment Study I. A clinicaltrial of abciximab in elective percutaneous coronary intervention after pretreatmentwith clopidogrel. N Engl J Med 2004;350(3):232–238 783. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ,Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A,DesmetW, RutschW, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Long-termefficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs.heparin andplanned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization:REPLACE-2 randomized trial. JAMA 2004;292(6):696–703 784. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA,Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA,Dirschinger J, Richardt G, Berger PB, Schomig A, Investigators I-RT. Bivalirudinvs. unfractionated heparin during percutaneous coronary intervention. N Engl JMed 2008;359(7):688–696 785. Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, Laugwitz K,Neumann F, Seyfarth M, Berger P, Scho¨mig A, Kastrati A. Bleeding after percutaneouscoronary intervention with Bivalirudin or unfractionated Heparin andone-year mortality. Am J Cardiol 2010;105(2):163–167 786. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C,Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 2006;355(10):1006–1017 787. Montalescot G, Gallo R, White HD, Cohen M, Steg PG, Aylward PE, Bode C,Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneouscoronary intervention patients, an international randomized evaluation)trial. JACC Cardiovasc Interv 2009;2(11):1083–1091 788. Silvain J, Beygui F, Barthe´le´my O, Pollack C Jr., Cohen M, Zeymer U, Huber K,Goldstein P, Cayla G, Collet J-P, Vicaut E, Montalescot G. Efficacy and safety ofenoxaparin vs. unfractionated heparin during percutaneous coronary intervention:systematic review and meta-analysis. BMJ 2012;344 789. Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A. Effectiveness ofin-laboratory high-dose clopidogrel loading vs. routine pre-load in patients undergoingpercutaneous coronary intervention: results of the ARMYDA-5 PRELOAD(Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)randomized trial. J Am Coll Cardiol 2010;56(7):550–557 790. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG,Slama M, Milleron O, Collet JP,Henry P, Beygui F, Drouet L.Arandomized comparisonof high clopidogrel loading doses in patients with non-ST-segment elevationacute coronary syndromes: the ALBION (Assessment of the Best Loading Doseof Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)trial. J Am Coll Cardiol 2006;48(5):931–938 791. Steinhubl SR, Berger S, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ, for theCredo I. Early and sustained dual oral antiplatelet therapy following percutaneouscoronary intervention. JAMA 2002;288:2411–2418 792. Widimsky P, Motovska Z, Simek S, Kala P, Pudil R, Holm F, Petr R, Bilkova D,Skalicka H, Kuchynka P, Poloczek M, Miklik R, Maly M, Aschermann M. Clopidogrelpre-treatment in stable angina: for all patients.6 h before elective coronary angiographyor only for angiographically selected patients a few minutes before PCI? Arandomized multicentre trial PRAGUE-8. Eur Heart J 2008;29(12):1495–1503 793. Collaborative overview of randomised trials of antiplatelet therapy:I: Prevention ofdeath, myocardial infarction, and stroke by prolonged antiplatelet therapy invarious categories of patients. Antiplatelet Trialists’ Collaboration. BMJ (Clinical researched.) 1994;308(6921):81–106 794. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J,Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A Aspirin in the primary and secondary prevention of vascular disease: collaborativemeta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849–1860 795. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of thesafety of clopidogrel with and without a loading dose in combination with aspirincompared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation2000;102(6):624–629 796. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrelafter intracoronary stent implantation in a broad patient population. Circulation2001;104(5):539–543 797. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogreland aspirin vs. ticlopidine and aspirin after the placement of coronary-arterystents. Circulation 2000;101(6):590–593 798. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900 mgloading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stentingand Antithrombotic Regimen: Choose Between 3 High Oral Doses for ImmediateClopidogrel Effect) Trial. Circulation 2005;112(19):2946–2950 799. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F,Colombo F, Tebaldi M, Fuca` G, Kubbajeh Md, Cangiano E, Minarelli M,Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G,Ferrari R. Short- vs. long-term duration of dual-antiplatelet therapy after coronarystenting: a randomized multicenter trial. Circulation 2012;125(16):2015–2026 800. Scho¨mig A,NeumannFJ, Kastrati A, Schu¨hlen H, Blasini R, Hadamitzky M,Walter H,Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K.Arandomized comparisonof antiplatelet and anticoagulant therapy after the placement of coronary-arterystents. N Engl J Med 1996;334(17):1084–1089 801. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A,Diver DJ, Lasorda DM, WilliamsDO, Pocock SJ, Kuntz RE.Aclinical trial comparingthree antithrombotic-drug regimens after coronary-artery stenting. Stent AnticoagulationRestenosis Study Investigators. N Engl J Med 1998;339(23):1665–1671 802. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dualantiplatelet therapy after percutaneous coronary interventions in the drug-elutingstent era: a meta-analysis of randomized trials. Eur Heart J 2012;33(24):3078–3087 803. GwonHC,Hahn JY, ParkKW, Song YB, Chae IH, Lim DS, HanKR, Choi JH, Choi SH,Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, ChungWY, Choi YJ, Hur SH,Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Sixmonthvs. 12-month dual antiplatelet therapy after implantation of drug-elutingstents: the Efficacy of Xience/Promus Vs. Cypher to Reduce Late Loss After Stenting(EXCELLENT) randomized, multicenter study. Circulation 2012;125(3):505–513 804. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB,Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela E,Perin MA, Devito FS, Labrunie A, Salvadori D, Gusma˜o M, Staico R, Costa JR, deCastro JP, Abizaid AS, Bhatt DL. Three vs.Twelve Months of Dual AntiplateletTherapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial JAMA 2013;310(23):2510–2522 805. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE,KangWC,Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y.Anew strategy for discontinuationof dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stentimplantation). J Am Coll Cardiol 2012;60(15):1340–1348 806. Schulz S, Mehilli J,NeumannFJ, SchusterT, Massberg S, Valina C, Seyfarth M, Pache J,Laugwitz KL, Buttner HJ, Ndrepepa G, Schomig A, Kastrati A. ISAR-REACT 3A: astudy of reduced dose of unfractionated heparin in biomarker negative patientsundergoing percutaneous coronary intervention. Eur Heart J 2010;31(20):2482–2491 807. Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet JP,Steinhubl SR, Montalescot G. Intravenous low-molecular-weight heparins comparedwith unfractionated heparin in percutaneous coronary intervention: quantitativereview of randomized trials. Arch Intern Med 2007;167(22):2423–2430 808. Mehran R, Pocock SJ, StoneGWet al. Associations of major bleeding and myocardialinfarction with the incidence and timing of mortality in patients presenting withnon-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial Eur Heart J 2009;30:1457–1466 809. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY,Gibler WB, Ohman EM, Roe MT, Pollack CV Jr., Peterson ED, Alexander KP. Baselinerisk of major bleeding in non-ST-segment-elevation myocardial infarction: theCRUSADE (Can Rapid risk stratification of Unstable angina patients SuppressADverse outcomes with Early implementation of the ACC/AHA Guidelines)Bleeding Score. Circulation 2009;119(14):1873–1882 810. Pena A, Collet JP, Hulot JS, Silvain J, Barthe´le´my O, Beygui F, Funck-Brentano C,Gilles M. Can we override clopidogrel resistance? Circulation 2009;119(21):2854–2858 811. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG,Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC,Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL,Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR,Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M,McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K,Hochman JS, Ohman EM. Prasugrel vs. clopidogrel for acute coronary syndromeswithout revascularization. N Engl J Med 2012;367(14):1297–1309 812. Mehta S, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP,Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP,Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD,Chrolavicius S, Gao P, Fox KAA, Yusuf S, on behalf of the CI. Double-dose vs standard-dose clopidogrel and high-dose vs. low-dose aspirin in individuals undergoingpercutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233–1243 813. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van deWerf F, deTorbal A, Armstrong PW,Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ,SimoonsML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: ameta-analysis of all major randomised clinical trials. Lancet 2002;359(9302):189–198 814. Kastrati A, Mehilli J, Neumann F-J, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M,Pache J, Seyfarth M, Schu¨hlen H, Dirschinger J, Berger PB, Scho¨mig A. Abciximab inpatients with acute coronary syndromes undergoing percutaneous coronary interventionafter clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA2006;295(13):1531–1538 815. StoneGW,McLaurinBT,CoxDA, Bertrand ME, Lincoff AM, MosesJW, WhiteHD,Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H,Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J,Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes N Engl J Med 2006;355(21):2203–2216 816. StoneGW,Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD,Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC,Mehran R, Pocock SJ. Antithrombotic strategies in patients with acute coronarysyndromes undergoing early invasive management: one-year results from theACUITY trial. JAMA 2007;298(21):2497–2506 817. Kastrati A, Neumann F-J, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz K-L,Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Scho¨mig A, Berger PB,Mehilli J. Abciximab and heparin vs. bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 2011;365(21):1980–1989 818. O’Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A,Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efficacy safetyof prasugrel with without a glycoprotein IIb/IIIa inhibitor in patients with acute coronarysyndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trialto Assess Improvement in Therapeutic utcomes by Optimizing Platelet InhibitionWith Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am CollCardiol 2009;54(8):678–685 819. Cohen M, Mahaffey KW, Pieper K, Pollack CV Jr., Antman EM, Hoekstra J,Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ. A subgroup analysisof the impact of prerandomization antithrombin therapy on outcomes in theSYNERGY trial: enoxaparin vs. unfractionated heparin in non-ST-segment elevationacute coronary syndromes. J Am Coll Cardiol 2006;48(7):1346–1354 820. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ,Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P,Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S,Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL,Pepine CJ, RuzylloW, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H. Enoxaparinvs.unfractionated heparin in high-risk patients with non-ST-segment elevationacute coronary syndromes managed with an intended early invasivestrategy: primary results of the SYNERGY randomized trial. JAMA 2004;292(1):45–54 821. Kastrati A, Neumann F-J, Mehilli J, Byrne RA, Iijima R, Bu¨ttner HJ, Khattab AA,Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA,Dirschinger J, Richardt G, Berger PB, Scho¨mig A. Bivalirudin vs. unfractionatedheparin during percutaneous coronary intervention. N Engl J Med 2008;359(7):688–696 822. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S,Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG,Bassand J-P, Wallentin L, Joyner C, Fox KAA. Comparison of fondaparinux andenoxaparin in acute coronary syndromes. N Engl J Med 2006;354(14):1464–1476 823. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP,Emanuelsson H, Finkelstein A HS, Katus H, Kilhamn J, Olofsson S, Storey RF,Weaver WD, Wallentin L, for the PSG. Ticagrelor Vs. Clopidogrel in PatientsWith ST-Elevation Acute Coronary Syndromes Intended for Reperfusion WithPrimary Percutaneous Coronary Intervention: A Platelet Inhibition and PatientOutcomes (PLATO) Trial Subgroup Analysis. Circulation 2010;122(21):2131–2141 824. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes DeLuna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparinprevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardialinfarction. Results of the thrombolysis in myocardial infarction (TIMI) 11Btrial. Circulation 1999;100(15):1593–1601 825. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K,Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatmentwith clopidogrel and aspirin followed by long-term therapy in patients undergoingpercutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527–533 826. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J-F, TenBerg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J,Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E,Widimsky P, the AI. Pretreatment with Prasugrel in Non-ST-Segment ElevationAcute Coronary Syndromes. N Engl J Med 2013;369(11):999–1010 827. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL,Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B,Joyner C, Pogue J, Yusuf S. Low-dose vs.standard-dose unfractionated heparin forpercutaneous coronary intervention in acute coronary syndromes treated withfondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010;304(12):1339–1349 828. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH,Antman EM, investigators T-T. Prasugrel compared with clopidogrel in patientsundergoing percutaneous coronary intervention for ST-elevation myocardial infarction(TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723–731 829. Erlinge D, Ten Berg J, Foley D, Angiolillo DJ,Wagner H, Brown PB, Zhou C, Luo J,Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ. Reduction inplatelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior toprasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. JAm Coll Cardiol 2012;60(20):2032–2040 830. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, Barthe´le´my O,Collet JP, Montalescot G. New P2Y12 inhibitors vs. clopidogrel in percutaneouscoronary intervention: a meta-analysis. J Am Coll Cardiol. 2010;56(19):1542–1551 831. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitorsamong patients with ST-segment elevation myocardial infarction treated withprimary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J2009;30:2705–2713 832. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P,Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P. Platelet glycoproteinIIb/IIIa inhibition with coronary stenting for acute myocardial infarction. NEngl J Med 2001;344(25):1895–1903 833. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP,Schmitt C, Seyfarth M, Dirschinger J, Schomig A. Evaluation of prolonged antithromboticpretreatment ("cooling-off" strategy) before intervention in patientswith unstable coronary syndromes: a randomized controlled trial. JAMA 2003;290(12):1593–1599 834. Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A,Neuman F-J, Effron MB, Barnathan ES, Topol EJ, Ellis SG, Investigators F. Benefitof facilitated percutaneous coronary intervention in high-risk ST-segment elevationmyocardial infarction patients presenting to nonpercutaneous coronary interventionhospitals. JACC Cardiovascular Interventions 2009;2(10):917–924 835. Van’t Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W,Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P,Giannitsis E, Hamm C, Ongoing Tirofiban In Myocardial infarction Evaluation 2study g. Prehospital initiation of tirofiban in patients with ST-elevation myocardialinfarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind,randomised controlled trial. Lancet 2008;372(9638):537–546 836. en Berg JM, van ’t HofAW, Dill T, Heestermans T, vanWerkum JW, Mosterd A, vanHouwelingen G, Koopmans PC, Stella PR, Boersma E,HammC. Effect of early, prehospitalinitiation of high bolus dose tirofiban in patients with ST-segment elevationmyocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol2010;55(22):2446–2455 837. Montalescot G. Mechanical reperfusion: treat well, treat on time too. Lancet 2008;372(9638):509–510 838. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH,Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S,El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R,Gibson CM. Intracoronary abciximab and aspiration thrombectomy in patientswith large anterior myocardial infarction: the INFUSE-AMI randomized trial JAMA 2012;307(17):1817–1826 839. Thiele H, Wo¨ hrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P,Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S,Schuler G. Intracoronary vs. intravenous bolus abciximab during primary percutaneouscoronary intervention in patients with acute ST-elevation myocardial infarction:a randomise trial. Lancet 2012;379(9819):923–931 840. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G,Wong SC, Kirtane AJ,Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 2008;358(21):2218–2230 841. Steg PG, van ’t HofAW,HammCW, Clemmensen P, Lapostolle F, Coste P, Berg JT,Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Orto MC, Nef H, Steinmetz J,Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton TC,Pocock SJ, Hamon M, Goldstein P. Bivalirudin Started during Emergency Transportfor Primary PCI. N Engl J Med 2013;369(23):2207–2217 842. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C,Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S,Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH; for the HEAT-PPCItrial investigators. Unfractionated heparin versus bivalirudin in primary percutaneouscoronary intervention (HEAT-PPCI): an open-label, single centre, randomisedcontrolled trial. Lancet 2014.doi: 10.1016/S0140-6736(14)60924-7 843. Richardt G. Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial. EurHeart J. Published online 9 May 2014; doi: 10.1093/eurheartj/ehu182 844. Collet J-P, Huber K, Cohen M, Zeymer U, Goldstein P, Pollack C Jr., Silvain J,Henry P, Varenne O, Carrie´ D, Coste P, Angioi M, Le Breton H, Cayla G,Elhadad S, Teiger E, Filippi E, Aout M, Vicaut E, Montalescot G, Investigators A. ADirect Comparison of Intravenous Enoxaparin With Unfractionated Heparin inPrimary Percutaneous Coronary Intervention (from the ATOLL Trial). Am JCardiol 2013;112(9):1367–1372 845. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ,Bassand JP,Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality andreinfarction in patients with acute ST-segment elevation myocardial infarction: theOASIS-6 randomized trial. JAMA 2006;295(13):1519–1530 846. Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Scholler R, Zahn R,Diller F, Darius H, Dill T, Huber K. Efficacy and safety of a high loading dose of clopidogreladministered prehospitally to improve primary percutaneous coronaryintervention in acute myocardial infarction: the randomized CIPAMI trial. Clin ResCardiol 2012;101(4):305–312 847. Koul S, Smith JG, Schersten F, James S, Lagerqvist B, Erlinge D. Effect of upstreamclopidogrel treatment in patients with ST-segment elevation myocardial infarctionundergoing primary percutaneous coronary intervention. Eur Heart J 2011;32(23):2989–2997 848. Dorler J, Edlinger M, Alber HF, Altenberger J, Benzer W, Grimm G, Huber K,Pachinger O, Schuchlenz H, Siostrzonek P, Zenker G, Weidinger F. Clopidogrelpre-treatment is associated with reduced in-hospital mortality in primary percutaneouscoronary intervention for acute ST-elevation myocardial infarction. Eur HeartJ 2011;32(23):2954–2961 849. De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M,Gabriel HM, Zorman S, De Carlo M, Rakowski T, Gyongyosi M, Dudek D. Earlyglycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results(EGYPT-ALT) cooperation: individual patient’s data meta-analysis. Journal of Thrombosisand Haemostasis: JTH 2011;9(12):2361–2370 850. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P,Margenet A, Huber K, Pollack C, Be´nezet JF, Stibbe O, Filippi E, Teiger E, Cayla G,Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E, forthe AI. Intravenous Enoxaparin or Unfractionated Heparin in Primary PercutaneousCoronary Intervention for ST-Elevation Myocardial Infarction. Lancet 2011;378(9792):693–703 851. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL,Sapp SK,Wolski K, Bhatt DL, Topol EJ. Triple antiplatelet therapy during percutaneouscoronary intervention is associated with improved outcomes includingone-year survival: results from the Do Tirofiban and ReoProGive Similar EfficacyOutcome Trial (TARGET). J Am Coll Cardiol 2003;42(7):1188–1195 852. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ,Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky´ P, Tousek F, Tauth J,Spriggs D, McLaurin BT, Angiolillo DJ, Ge´ne´reux P, Liu T, Prats J, Todd M,Skerjanec S, White HD, Harrington RA. Effect of Platelet Inhibition with Cangrelorduring PCI on Ischemic Events. N Engl J Med 2013;368(14):1303–1313 853. Steg PG, Bhatt DL, HammCW, StoneGW, Gibson CM, MahaffeyKW, Leonardi S,Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, GogiaHS, Gruberg L, French WJ,White HD, Harrington RA. Effect of cangrelor on periprocedural outcomes in percutaneouscoronary interventions: a pooled analysis of patient-level data. Lancet2013;382(9919):1981–1992 854. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ,Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T,Montalescot G, Manoukian SV, Prats J, Topol EJ. Bridging antiplatelet therapywith cangrelor in patients undergoing cardiac surgery: a randomized controlledtrial. JAMA 2012;307(3):265–274 855. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,Schneider D, Sun X, Verheugt FW, Gibson CM, the AACSTI. Rivaroxaban inPatients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366:9–19 856. Gibson CM,Chakrabarti AK, Mega J, Bode C, Bassand J-P, VerheugtFWA, Bhatt DL,Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E,Investigators A-AT. Reduction of Stent Thrombosis in Patients With Acute CoronarySyndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am CollCardiol 2013;62(4):286–290 857. Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG,Parkhomenko A, Tendera M, Widimsky P, Gibson CM. Rivaroxaban in patients stabilizedafter a ST-segment elevation myocardial infarction: results from the ATLASACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Additionto Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis InMyocardial Infarction-51). J Am Coll Cardiol 2013;61(18):1853–1859 858. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S,Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, DeCaterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D,Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R,White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L,Investigators A-. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med. 2011;365(8):699–708 859. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JGP, Van deWerf F, Wallentin L. Dabigatran vs. placebo in patients with acute coronary syndromeson dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 2011;32(22):2781–2789 860. Steg PG, Mehta SR, Jukema JW, Lip GYH, Gibson CM, Kovar F, Kala P,Garcia-Hernandez A, Renfurm RW, Granger CB. RUBY-1: a randomized, doubleblind,placebo-controlled trial of the safety and tolerability of the novel oral factorXa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J2011;32(20):2541–2554 861. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA,Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J,Mohan P, Montalescot G, Ruda M, RuzylloW, Verheugt F,Wallentin L. Apixaban,an oral, direct, selective factor Xa inhibitor, in combination with antiplatelettherapy after acute coronary syndrome: results of the Apixaban for Preventionof Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877–2885 862. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V,Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxabanvs. placebo in patients with acute coronarysyndromes (ATLASACS-TIMI46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29–38 863. Ruiz-Nodar JM, Marı´n F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR,Sogorb F, Valde´s M, Lip GYH. Anticoagulant and antiplatelet therapy use in 426patients with atrial fibrillation undergoing percutaneous coronary interventionand stent implantation implications for bleeding risk and prognosis. J Am CollCardiol 2008;51(8):818–825 864. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N,Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE,Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapywith warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Archives ofInternal Medicine 2010;170(16):1433–1441 Íå íàøëè, ÷òî èñêàëè? Âîñïîëüçóéòåñü ïîèñêîì:
|